SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AGE, GRPH, FIXX

NEW YORK, Feb. 27, 2024

AgeX Therapeutics, Inc. (NYSE: AGE)'s merger with Serina Therapeutics, Inc. Upon completion of the merger, pre-merger AgeX stockholders are expected to own approximately 25% of the newly combined company. If you are an AgeX shareholder, click here to learn more about your rights and options.

Graphite Bio, Inc. (NASDAQ: GRPH)'s merger with LENZ Therapeutics. Graphite shareholders are expected to own approximately 35% of the combined company upon the closing of the merger. If you are a Graphite shareholder, click here to learn more about your rights and options.  

Homology Medicines, Inc. (NASDAQ: FIXX)'s merger with Q32 Bio Inc. Upon completion of the proposed transaction, Homology shareholders are expected to own approximately 25% of the combined company. If you are a Homology shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.